Biopharmaceutical company Kamada has been granted an orphan drug designation (ODD) by the US Food and Drug Administration (FDA) for its Alpha-1 Antitrypsin (AAT) drug to treat type 1 diabetes.
The company is currently undergoing a Phase I/II clinical trial with AAT by IV route of administration.
Go deeper with GlobalData
AAT IV was granted FDA approval in July 2010 for the treatment of Alpha 1 deficiency and is exclusively marketed by Baxter in the US.
Kamada’s next-generation AAT by inhalation is currently undergoing a Phase 2-3 trial in Europe.
The company has already completed five clinical trials with its high purity, liquid formulation of inhaled Alpha-1 Antitrypsin.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
